Short answer
Larimar Therapeutics, Inc. (LRMR) filed its Q3 2026 10-Q quarterly report on Nov 16, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$31M
- +34.7% YoY · +5.0% QoQ
Source: XBRL data from the Larimar Therapeutics, Inc. (LRMR) Q3 2026 10-Q on SEC EDGAR. USD.
Larimar Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no product sales
- Net loss $31.1M vs $47.7M YoY, operating loss $32.5M vs $49.5M
- R&D expenses $25.9M vs $44.9M, G&A $6.5M vs $4.6M
- Operating cash outflow $119.8M through nine months, cash and securities $128.7M
- BLA submission completed November 2026, planned launch third quarter 2027 if approved, cash expected through late Q2 2027
Risk Factors
- BLA filing risk: FDA may refuse filing or deny accelerated approval for nomlabofusp
- Safety database risk: FDA identified adequacy as a review issue at BLA submission
- Manufacturing compliance risk: Fill-finish manufacturer received FDA Form 483
- Launch timing risk: Vendor remediation could delay potential approval or launch
- Supply-chain risk: Additional fill-finish manufacturer remains under qualification
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Larimar Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.